Sylvester P W, Ip M M
Prostate. 1987;10(1):57-67. doi: 10.1002/pros.2990100109.
Tamoxifen (TAM) has previously been shown to inhibit growth of the Dunning R3327 rat prostate adenocarcinoma and to elevate serum prolactin levels. The purpose of this study was to determine the role of prolactin in modulating the effects of tamoxifen on growth of the R3327 prostatic adenocarcinoma. Intact and castrated Copenhagen-Fischer male rats bearing the Dunning R3327 rat prostatic tumor were divided into groups and injected sc five times per week for 16 weeks as follows: vehicle; TAM (0.5 mg/kg); haloperidol (HALO; 0.5 mg/kg); bromocriptine (CB-154; 5 mg/kg); TAM plus HALO; or TAM plus CB-154. In both intact and castrated rats, agents that either raised (HALO) or lowered (CB-154) serum prolactin had little effect on prostatic tumor growth when administered singly. In intact rats, average tumor diameter in vehicle-treated controls increased 421% 16 weeks after the start of the experiment, and treatment with TAM or TAM plus HALO reduced this tumor growth by approximately one-half. Interestingly, CB-154 administered in combination with TAM completely blocked TAM inhibition of tumor growth in intact rats. In contrast to these results in intact rats, average tumor diameter increased 129% in TAM- and 118% in TAM plus HALO-treated castrated rats and was significantly greater than the characteristic retardation of tumor growth (49% increase) that occurred in the vehicle-treated castrate controls. In addition, combined treatment of TAM plus CB-154 in castrate rats resulted in an even greater increase (188%) in average tumor diameter. The inhibitory effect of TAM on R3327 prostatic tumor growth in intact rats appears to be an indirect effect resulting from its ability to reduce serum testosterone levels. In contrast, the stimulatory effect of TAM in castrate rats appears to result directly from an estrogen-like action, which can directly enhance prostatic tumor growth in the presence of low levels of circulating androgens; this stimulatory effect of TAM is more pronounced when prolactin levels are suppressed by CB-154. Clearly, castration alone is more effective than TAM therapy alone or in combination with castration in the retardation of the growth of the androgen-dependent R3327 prostatic tumor in rats.
他莫昔芬(TAM)此前已被证明可抑制邓宁R3327大鼠前列腺腺癌的生长并提高血清催乳素水平。本研究的目的是确定催乳素在调节他莫昔芬对R3327前列腺腺癌生长的影响中的作用。将患有邓宁R3327大鼠前列腺肿瘤的完整和去势哥本哈根-费舍尔雄性大鼠分成几组,每周皮下注射5次,共16周,具体如下:赋形剂;他莫昔芬(0.5毫克/千克);氟哌啶醇(HALO;0.5毫克/千克);溴隐亭(CB - 154;5毫克/千克);他莫昔芬加HALO;或他莫昔芬加CB - 154。在完整和去势大鼠中,单独给予升高(HALO)或降低(CB - 154)血清催乳素的药物对前列腺肿瘤生长几乎没有影响。在完整大鼠中,实验开始16周后,赋形剂处理的对照组中肿瘤平均直径增加了421%,而他莫昔芬或他莫昔芬加HALO治疗使肿瘤生长减少了约一半。有趣的是,在完整大鼠中,CB - 154与他莫昔芬联合给药完全阻断了他莫昔芬对肿瘤生长的抑制作用。与完整大鼠中的这些结果相反,在他莫昔芬治疗的去势大鼠中肿瘤平均直径增加了129%,在他莫昔芬加HALO治疗的去势大鼠中增加了118%,且显著大于赋形剂处理的去势对照组中肿瘤生长的特征性迟缓(增加49%)。此外,在去势大鼠中他莫昔芬加CB - 154联合治疗导致肿瘤平均直径增加得更多(188%)。他莫昔芬对完整大鼠中R3327前列腺肿瘤生长的抑制作用似乎是其降低血清睾酮水平能力所产生的间接作用。相比之下,他莫昔芬在去势大鼠中的刺激作用似乎直接源于类似雌激素的作用,在循环雄激素水平较低的情况下,这种作用可直接增强前列腺肿瘤生长;当CB - 154抑制催乳素水平时,他莫昔芬的这种刺激作用更为明显。显然,在延缓大鼠雄激素依赖性R3327前列腺肿瘤生长方面,单纯去势比单独使用他莫昔芬治疗或他莫昔芬与去势联合治疗更有效。